An FP-CIT PET comparison of the differences in dopaminergic neuronal loss between idiopathic Parkinson disease with dementia and without dementia

Alzheimer Disease and Associated Disorders
In-Uk SongYong-An Chung

Abstract

Previous studies have demonstrated a decreased density of dopamine transporters (DAT) in basal ganglia in patients with idiopathic Parkinson disease (IPD) using I-n-fluoropropyl-2b-carbomethoxy-3b-(4-iodophenyl) nortropane (FP-CIT), and the reductions in striatal DAT levels were inversely correlated with the severity of motor dysfunction in IPD. However, there has been no study on the correlation of DAT levels between IPD patients with and without cognitive dysfunction. Thus, we evaluated the differences in regional DAT density in the brain of patients with IPD without dementia and those with dementia using FP-CIT positron emission tomography. We recruited 24 consecutive patients with IPD, including 7 with IPD without dementia and 17 with IPD with dementia, and 18 healthy controls. FP-CIT positron emission tomography scans were acquired 90 and 210 minutes after the FP-CIT injection. The DAT density did not differ in the caudate nucleus or the putamen between patients with IPD without dementia and those with dementia. However, the DAT density between the 2 groups with IPD demonstrated a significantly decreased density compared with that of healthy controls in the putamen. We cautiously suggest that there is no relationship betwe...Continue Reading

References

Mar 1, 1992·Journal of Neurology, Neurosurgery, and Psychiatry·A J HughesA J Lees
Feb 1, 1993·Archives of Neurology·A J HughesA J Lees
Aug 6, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·H T BenamerD G Grosset
Mar 26, 2002·Brain : a Journal of Neurology·Andrew J HughesAndrew J Lees
Jul 10, 2003·Lancet Neurology·Murat Emre
Jan 26, 2005·Neurology·B RavinaR Holloway
Oct 18, 2005·European Journal of Nuclear Medicine and Molecular Imaging·S A EshuisP L Jager
Mar 14, 2007·Journal of Neurology, Neurosurgery, and Psychiatry·Zuzana WalkerCornelius L E Katona
Jun 26, 2009·Parkinsonism & Related Disorders·Carlo RossiRoberto Ceravolo

❮ Previous
Next ❯

Citations

May 20, 2016·Movement Disorders : Official Journal of the Movement Disorder Society·Manuel Delgado-AlvaradoMaría C Rodriguez-Oroz
Mar 4, 2017·Nature Reviews. Neurology·Dag AarslandClive Ballard
Apr 1, 2017·Annals of Nuclear Medicine·Soichiro ShimizuHaruo Hanyu
Sep 1, 2017·Dementia and Neurocognitive Disorders·YoungSoon YangYong Tae Kwak
Aug 15, 2020·Annals of Clinical and Translational Neurology·Yanyan KongYihui Guan
Mar 1, 2021·Journal of the Neurological Sciences·Ryuichi TakahashiKazumasa Yokoyama
Sep 22, 2017·Neurobiology of Aging·Ji Hyun KoUNKNOWN Alzheimer's Disease Neuroimaging Initiative
May 3, 2013·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Morten ZiebellSteen G Hasselbalch

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal ganglia in Parkinson's disease (MDS)

The basal ganglia is comprised of the neostriatum, the external and internal pallidal segments, the subthalamic nucleus, the substantia nigra pars reticulata, and the pars compacta of the substantia nigra. The basal ganglia circuitry is responsible for the correct execution of voluntary movements and is implicated in Parkinson's disease. Here is the latest research investigating the basal ganglia in Parkinson's disease.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.